Vaxxinity Inc(VAXX)
$0.02-0.01 (-40.00%)
VAXX
Vaxxinity Inc stock drug pipeline
$0.02
At close:-0.01 (-40.00%)
Want to see VAXX full AI Analyst Report?
Vaxxinity Inc (VAXX) Drug Pipeline
144 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Vxx-401 | Hypercholesterolemia | Phase I | Active Not Recruiting | A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants | Feb 20, 2023 | ― |
| Ub-313 | Migraine | Phase I | Completed | A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants | Jul 20, 2022 | ― |
| Ub-612, Bnt162b2 Vaccine, Chadox1-S Vaccine, Sinopharm Bibp | Covid-19 Vaccines | Phase III | Unknown | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine | Mar 21, 2022 | ― |
| Ub-612 | Covid-19 | Phase I | Completed | A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | Jul 12, 2021 | ― |
| Ub-612 | Covid-19 | Phase II | Terminated | A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers | Feb 23, 2021 | ― |
| Ub-612 | Covid-19, Coronavirus, Sars-Cov-2 | phase2AndPhase3 | Withdrawn | A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine | Dec 10, 2020 | ― |
| Ub-612 | Covid-19 | Phase I | Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | Sep 02, 2020 | ― |
| Ub-312 | Parkinson's Disease, Parkinsonism | Phase I | Completed | Study of UB-312 in Healthy Participants and Parkinson's Disease Patients | Aug 05, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Vxx-401 | Phase I | Hypercholesterolemia | Active Not Recruiting | A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants | Feb 20, 2023 | ― |
| Ub-313 | Phase I | Migraine | Completed | A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants | Jul 20, 2022 | ― |
| Ub-612, Bnt162b2 Vaccine, Chadox1-S Vaccine, Sinopharm Bibp | Phase III | Covid-19 Vaccines | Unknown | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine | Mar 21, 2022 | ― |
| Ub-612 | Phase I | Covid-19 | Completed | A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | Jul 12, 2021 | ― |
| Ub-612 | Phase II | Covid-19 | Terminated | A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers | Feb 23, 2021 | ― |
| Ub-612 | phase2AndPhase3 | Covid-19, Coronavirus, Sars-Cov-2 | Withdrawn | A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine | Dec 10, 2020 | ― |
| Ub-612 | Phase I | Covid-19 | Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | Sep 02, 2020 | ― |
| Ub-312 | Phase I | Parkinson's Disease, Parkinsonism | Completed | Study of UB-312 in Healthy Participants and Parkinson's Disease Patients | Aug 05, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vaxxinity Inc (VAXX) have in its pipeline
Vaxxinity Inc VAXX is currently developing the following drugs: Vxx-401, Ub-313, Ub-612, Bnt162b2 Vaccine, Chadox1-S Vaccine, Sinopharm Bibp, Ub-612, Ub-312. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
